Literature DB >> 16676006

c-Jun promotes cellular survival by suppression of PTEN.

K Hettinger1, F Vikhanskaya, M K Poh, M K Lee, I de Belle, J-T Zhang, S A G Reddy, K Sabapathy.   

Abstract

Activation of c-Jun, a component of the AP-1 family of transcription factors, leads to either promotion or prevention of apoptosis. However, the molecular determinants of c-Jun-mediated cell survival are still unclear. We show here that inducible expression of c-Jun promotes cellular survival by negatively regulating the expression of the tumor-suppressor PTEN, resulting in the concomitant activation of the Akt survival pathway. Consistently, c-jun-/- fibroblasts, which are sensitive to nutrient deprivation, and human cell lines in which c-Jun expression is silenced, express elevated levels of PTEN. siRNA-mediated silencing of PTEN resulted in the reduction of cell-death owing to c-Jun deficiency. c-Jun was found to suppress PTEN expression by binding to a variant AP-1 site found in the 5' upstream sequences of PTEN promoter. Finally, an inverse correlation between c-Jun and PTEN levels was apparent in a panel of human tumor cell lines, independent of their p53 status. Together, the data demonstrate that c-Jun contributes to the promotion of cellular survival by regulating the expression of PTEN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676006     DOI: 10.1038/sj.cdd.4401946

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  60 in total

1.  LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1α translation.

Authors:  C Zhou; C Huang; J Wang; H Huang; J Li; Q Xie; Y Liu; J Zhu; Y Li; D Zhang; Q Zhu; C Huang
Journal:  Oncogene       Date:  2017-03-06       Impact factor: 9.867

2.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 4.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

Review 5.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

6.  Targeting metastatic upper gastrointestinal adenocarcinomas.

Authors:  Jennifer L Spratlin; Quincy Chu; Sheryl Koski; Karen King; Karen Mulder
Journal:  World J Clin Oncol       Date:  2011-03-10

Review 7.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

8.  ΔNp63α promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.

Authors:  Ting Hao; Ye-Hua Gan
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

9.  PPARgamma, PTEN, and the Fight against Cancer.

Authors:  Rosemary E Teresi; Kristin A Waite
Journal:  PPAR Res       Date:  2008-12-14       Impact factor: 4.964

10.  UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes.

Authors:  M Ming; W Han; J Maddox; K Soltani; C R Shea; D M Freeman; Y-Y He
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.